Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06041529
Other study ID # YMC050
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date September 14, 2023
Est. completion date June 27, 2025

Study information

Verified date September 2023
Source Yuhan Corporation
Contact Yujun Kim
Phone +82-2-828-0394
Email yjkim@yuhan.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations


Description:

This is a Phase IV, Randomized, Open-label, Superiority, Comparative study evaluating the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination) versus Telmisartan, Amlodipine, and Hydrochlorothiazide in eledrly patient with essential hypertension uncontrolled by Telmisartan and Amlodipine Combinations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 250
Est. completion date June 27, 2025
Est. primary completion date February 21, 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Signed informed consent 2. Aged = 65 with essential hypertension 3. Patient with uncontrolled essential hypertension at screening - If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg = MSSBP < 200 mmHg - If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg = MSSBP < 200 mmHg 4. Medication compliance of investigational product (Run-in) > 70 % 5. Patient who has measured nighttime blood pressure more than 7 times from the night before the randomized date to the morning of the day of the randomized date (22:00~5:59) 6. Patient with uncontrolled essential hypertension at Visit 2 - 140 mmHg = MSSBP < 200 mmHg Exclusion Criteria: 1. Patient who has secondary hypertension or suspected of secondary hypertension 2. Patient who has orthostatic hypotension with symptoms 3. Patient who has severe hypotension and severe heart disease (NYHA class III~IV) 4. Patient who has been diagnosed with or treated with the following diseases within the last 6 months judged by the investigator to be clinically significant - Patient who has ischemic heart disease, peripheral vascular disease, percutaneous transluminal coronary angioplasty, or coronary artery bypass surgery - Patient who has clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter, or other arrhythmia judged clinically significant by the investigator - Patient who has hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, aortic valve hemodynamically significant or mitral valve stenosis/reflux - Patient who has severe cerebrovascular disease - Known moderate or malignant retinopathy 5. Patient who has sleep disorders or apnea during sleep 6. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products 7. Patient who has untreated addison's disease, symptomatic hyperuricemia, hyperparathyroidism, sympathetic nerve resection, shock patients 8. Patient with anuria 9. History of malignant tumor 10. Patient with any chronic inflammation disease needed to chronic inflammation therapy 11. Patient with mental defects that may interfere with participation in clinical trials 12. Patient who has history of drug allergic reactions 13. Patient who has angioedema related to ACE inhibitors, ARBs or diuretics 14. Patient who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorpiton. 15. Known hypersensitivity to components of the investigational product 16. Patient who is unable to stop taking prohibited drugs 17. Test results showing the following values at screening - The change of MSSBP = 20 mmHg and MSDBP = 10 mmHg on target arm between 1st and 2nd measurements 18. Hepatic or renal dysfunction as defined by the following laboratory parameters (eGFR < 30 mL/min/1.73m2, Serum creatinine = 3 mg/dL, AST/ALT > UNL X 3) 19. Hypokalemia (Serum K < 3.0 mmol/L) or hyperkalemia (Serum K > 5.5 mmol/L), hyponatremia (Serum Na < 132.0 mmol/L) or uncontrolled diabetes (HbA1c > 9.0%) 20. Pregnant or lactating women 21. Patient who is unable to maintain proper night sleep 22. History of drug or alcohol dependency within 1 year prior to screening 23. Malnutrition, starvation, debilitating factors, A person who is being forcibly detained for the treatment of mental or physical 24. Administration of other investigational products within 3 months prior to screening. 25. An impossible one who participates in clinical trial by investigator's decision

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable

Locations

Country Name City State
Korea, Republic of The Catholic University of Korea Daejeon ST. Mary's Hospital Daejeon
Korea, Republic of Chonnam National University Hospital Gwangju
Korea, Republic of The Catholic University of Korea, ST. Vincent's Hospital Gyeonggi-do
Korea, Republic of he Catholic University of Korea, Incheon ST. Mary's Hospital Incheon
Korea, Republic of Hanyang university medical center Seoul
Korea, Republic of Korea University Guro Hospital Seoul
Korea, Republic of Seoul national University Budang hospital Seoul
Korea, Republic of The Catholic University of Korea Seoul
Korea, Republic of The Catholic University of Korea Bucheon St.Mary's Hospital Seoul Gyeonggi-do
Korea, Republic of The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul
Korea, Republic of The Catholic University of Korea, Uijeongbu ST. Mary's Hospital Seoul
Korea, Republic of The Catholic University of Korea, Yeouido ST. Mary's Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yuhan Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Systolic Blood Pressure (MSBP) in nighttime To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 Week 8
Secondary Mean Systolic Blood Pressure (MSBP) in nighttime To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 26 if applicable Week 26 if applicable
Secondary Mean Diastolic Blood Pressure (MDBP) in nighttime To evaluate change from baseline in nighttime Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable Week 8 and Week 26 if applicable
Secondary Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) in daytime To evaluate change from baseline in daytime Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable Week 8 and Week 26 if applicable
Secondary 24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) To evaluate change from baseline in 24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable Week 8 and Week 26 if applicable
Secondary Patients Achieving in nighttime Mean Systolic Blood Pressure (MSBP) To evaluate the percentage of patients who reached the treatment goal for nighttime Mean Systolic Blood Pressure (MSBP) (<110/65mmHg) measured by Ambulatory Blood Pressure Monitoring at Week 8 Week 8
Secondary Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP) To evaluate change from baseline in Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP) measured by the Institution at Week 4, Week 8 and Week 26 if applicable Week 4, Week 8 and Week 26 if applicable
Secondary Patients Achieving in Mean Sitting Systolic Blood Pressure (MSSBP) - To evaluate the percentage of patients who reached the treatment goal for Mean Sitting Blood Pressure (MSBP) < 140/90 mmHg measured by the Institution at Week 4, Week 8 and Week 26 if applicable Week 4, Week 8 and Week 26 if applicable
Secondary Percentage of patients with decreased Mean Sitting Systolic Blood Pressure (MSSBP) and Mean Sitting Diastolic Blood Pressure (MSDBP). To evaluate the percentage of subjects with a Mean Sitting Systolic Blood Pressure (MSSBP) decrease of =20mmHg and a Mean Sitting Diastolic Blood Pressure (MSDBP) decrease of =10mmHg at Week 4, Week 8 and Week 26 if applicable Week 4, Week 8 and Week 26 if applicable
Secondary T/P ratio To evaluate the T/P ratio for systolic/diastolic blood pressure measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable Week 8 and Week 26 if applicable
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function
Completed NCT00741585 - Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Phase 4